Helix BioPharma Appoints New Board Member and Corporate Secretary, Advances Nasdaq Uplisting Strategy
Helix BioPharma strengthens its board and governance with seasoned capital markets and corporate secretarial expertise as it prepares for a Nasdaq listing under the MJDS framework.
Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced the immediate appointments of Zachary T. Stadnyk to its Board of Directors and Natalia L. Butterworth as Corporate Secretary, signaling a strategic push to enhance its capital markets and governance capabilities ahead of a planned Nasdaq uplisting.
Mr. Stadnyk, former Head of Life Sciences at the TSX and TSXV, brings over 15 years of experience in biotechnology capital markets, public company leadership, and strategic transactions. He has led and supported over $100 million in institutional financings and contributed to major deals such as the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. His expertise in public listings and capital formation is expected to be instrumental as Helix advances its financing and Nasdaq listing strategy through the Multijurisdictional Disclosure System (MJDS).
Ms. Butterworth, Director, Corporate Secretarial and Governance at ARO Consulting Inc., adds over 15 years of experience in governance and regulatory compliance across multiple jurisdictions, including the pharmaceutical, technology, and finance sectors. Based in British Columbia, both appointees strengthen the Company's Canadian capital markets and governance expertise.
“As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma. “Zach brings a wealth of experience across biotechnology financing, public markets and strategic transactions, while Natalia adds strong governance and corporate secretarial expertise. These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives.”
Mr. Stadnyk expressed enthusiasm about joining at a pivotal stage, noting the Company's differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing as compelling opportunities. Helix is also in the process of relocating its registered and records office from Toronto, Ontario to Vancouver, British Columbia, to align with its strengthened governance and capital markets infrastructure.
The appointments and office relocation underscore Helix's commitment to advancing its capital markets strategy, which includes preparing for a Nasdaq listing under the MJDS framework. The Company's pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its targeting foundation with next-generation bi-specific antibody-drug conjugates (ADCs) in discovery. Helix also advances two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug.
These strategic moves come as Helix prepares for a Nasdaq listing, which could provide greater access to U.S. capital markets and enhance shareholder value. The Company's forward-looking statements, including those regarding the Nasdaq listing, are subject to risks and uncertainties as detailed in its public filings on SEDAR+ at www.sedarplus.ca.